Litcius/Paper detail

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, John Wilding

2021The Lancet550 citationsDOIOpen Access PDF

Topics & Concepts

MedicineGlucagon-like peptide 1 receptorPharmacologyReceptorB2 receptorAgonistInternal medicineBradykininDiabetes Treatment and ManagementPharmacology and Obesity TreatmentMetabolism, Diabetes, and Cancer
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications | Litcius